ArticleApplied biochemistry and biotechnology2026
β-Cyclodextrin-Functionalized Sodium Alginate Nanocarrier Co-Loaded with Naringenin Attenuates Pregnancy-Induced Hypertension Via JAK/STAT3 Pathway Inhibition.
Article in Applied biochemistry and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pregnancy-induced hypertension (PIH) is a condition marked by elevated blood pressure during pregnancy, posing serious risks to both maternal and perinatal health, including increased mortality. Due to the safety concerns and side effects of current treatments for PIH, the search for new therapeutic agents is urgently needed. This study aimed to develop a β-cyclodextrin-functionalized sodium alginate (β-CD/SA) nanocarrier co-encapsulated with Naringenin (NR) to enhance its therapeutic potential. The β-CD/SA@NR nanocarriers were synthesized using ionic gelation and characterized by FTIR, XRD, and SEM, revealing a mean particle size of 142.6 ± 8.3 nm and an encapsulation efficiency of 68.4 ± 3.1%. A total of sixty pregnant mice were randomly assigned to five groups, with seven mice in each group (n = 7): control, PIH model, NR, β-CD/SA, and β-CD/SA@NR nanocarrier. Treatment with β-CD/SA@NR significantly reduced systolic blood pressure from 163.7 ± 5.2 mmHg to 123.5 ± 4.1 mmHg (p < 0.001), decreased urinary protein from 2.91 ± 0.27 mg/mL to 1.12 ± 0.13 mg/mL (p < 0.01), and increased fetal weights by 28.4% compared to the PIH group. Moreover, β-CD/SA@NR treatment downregulated JAK2 and STAT3 expression by 64.7% and 58.3%, respectively (p < 0.001), along with a significant reduction in IL-6 and TNF-α levels. These results indicate that β-CD/SA@NR nanocarriers effectively manage PIH by delivering NR to suppress JAK/STAT3 signaling, highlighting their translational potential as a safe maternal-fetal therapeutic strategy.
Indexed as
Identifiers
41533298What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.